Top

Published in:

Open Access 01-12-2017 | Research

Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates

Authors: Ronald J. Mandel, David J. Marmion, Deniz Kirik, Yaping Chu, Clifford Heindel, Thomas McCown, Steven J. Gray, Jeffrey H. Kordower

Published in: Acta Neuropathologica Communications | Issue 1/2017

Abstract

Multiple system atrophy (MSA) is a horrible and unrelenting neurodegenerative disorder with an uncertain etiology and pathophysiology. MSA is a unique proteinopathy in which alpha-synuclein (α-syn) accumulates preferentially in oligodendroglia rather than neurons. Glial cytoplasmic inclusions (GCIs) of α-syn are thought to elicit changes in oligodendrocyte function, such as reduced neurotrophic support and demyelination, leading to neurodegeneration. To date, only a murine model using one of three promoters exist to study this disease. We sought to develop novel rat and nonhuman primate (NHP) models of MSA by overexpressing α-syn in oligodendroglia using a novel oligotrophic adeno-associated virus (AAV) vector, Olig001. To establish tropism, rats received intrastriatal injections of Olig001 expressing GFP. Histological analysis showed widespread expression of GFP throughout the striatum and corpus callosum with >95% of GFP+ cells co-localizing with oligodendroglia and little to no expression in neurons or astrocytes. We next tested the efficacy of this vector in rhesus macaques with intrastriatal injections of Olig001 expressing GFP. As in rats, we observed a large number of GFP+ cells in gray matter and white matter tracts of the striatum and the corpus callosum, with 90–94% of GFP+ cells co-localizing with an oligodendroglial marker. To evaluate the potential of our vector to elicit MSA-like pathology in NHPs, we injected rhesus macaques intrastriatally with Olig001 expressing the α-syn transgene. Histological analysis 3-months after injection demonstrated widespread α-syn expression throughout the striatum as determined by LB509 and phosphorylated serine-129 α-syn immunoreactivity, all of which displayed as tropism similar to that seen with GFP. As in MSA, Olig001-α-syn GCIs in our model were resistant to proteinase K digestion and caused microglial activation. Critically, demyelination was observed in the white matter tracts of the corpus callosum and striatum of Olig001-α-syn but not Olig001-GFP injected animals, similar to the human disease. These data support the concept that this vector can provide novel rodent and nonhuman primate models of MSA.

Available only for authorised users

Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (1998) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 96:439–444CrossRefPubMed

Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T et al (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62(6):964–970. doi:10.1002/glia.22653 CrossRefPubMedPubMedCentral

Bleasel JM, Halliday GM, Kim WS (2016) Animal modeling an oligodendrogliopathy-multiple system atrophy. Acta Neuropathol Commun 4:12. doi:10.1186/s40478-016-0279-6 CrossRefPubMedPubMedCentral

Boudes M, Uvin P, Pinto S, Voets T, Fowler CJ, Wenning GK et al (2013) Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov Disord 28:347–355CrossRefPubMedPubMedCentral

Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288CrossRefPubMed

Burger C, Nguyen FN, Deng J, Mandel RJ (2005) Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther 11(2):327–331CrossRefPubMed

Castle MJ, Turunen HT, Vandenberghe LH, Wolfe JH (2016) Controlling AAV tropism in the nervous system with natural and engineered Capsids. Methods Mol Biol 1382:133–149. doi:10.1007/978-1-4939-3271-9_10 CrossRefPubMedPubMedCentral

Chen H, McCarty DM, Bruce AT, Suzuki K, Suzuki K (1998) Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther 5:50–58CrossRefPubMed

Clément N, Grieger JC (2016) Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev 3:16002. doi:10.1038/mtm.2016.2 CrossRefPubMedPubMedCentral

10.

Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S et al (2015) Alpha-Synuclein expression in the Oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Rep 5(2):174–184. doi:10.1016/j.stemcr.2015.07.002 Epub 2015 Jul 30CrossRef

11.

Dodiya HB, Bjorklund T, Stansell J 3rd, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar;18(3):579-87. doi:10.1038/mt.2009.216. Epub 2009 Sep 22. PubMed PMID: 19773746; PubMed Central PMCID: PMC2839447.

12.

Don AS, Hsiao JH, Bleasel JM, Couttas TA, Halliday GM, Kim W (2014) Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun 2(1):150. doi:10.1186/s40478-014-0150-6 CrossRefPubMedPubMedCentral

13.

Ettle B, Reiprich S, Deusser J, Schlachetzki JC, Xiang W, Prots I et al (2014) Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci 62:68–78. doi:10.1016/j.mcn.2014.06.012 CrossRefPubMed

14.

Ettle B, Schlachetzki JC, Winkler J (2016) Oligodendroglia and myelin in neurodegenerative diseases: more than just bystanders? Mol Neurobiol 53(5):3046–3062. doi:10.1007/s12035-015-9205-3 CrossRefPubMed

15.

Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(14):1375–1376. doi:10.1056/NEJMc1501657 PubMed

16.

Fernagut PO, Meissner WG, Biran M, Fantin M, Bassil F, Franconi JM et al (2014) Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 68:98–106CrossRefPubMed

17.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164CrossRefPubMed

18.

Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM et al (2005) The North American multiple system atrophy study group. J Neural Transm 112(12):1687–1694CrossRefPubMed

19.

Gorbatyuk OS, Li S, Nguyen FN, Manfredsson FP, Kondrikova G, Sullivan LF et al (2010) α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration. Mol Ther 18(10):1758–1768. doi:10.1038/mt.2010.137 Epub 2010 Jul 27CrossRefPubMedPubMedCentral

20.

Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ, Li W (2010) Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 18(3):570–578. doi:10.1038/mt.2009.292 Epub 2009 Dec 29CrossRefPubMed

21.

Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22(9):1143–1153. doi:10.1089/hum.2010.245 Epub 2011 Jun 1CrossRefPubMedPubMedCentral

22.

Grimm D, Zolotukhin S. E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal-Tailored Acceleration of AAV Evolution. Mol Ther. 2015 Dec;23(12):1819-1831. doi:10.1038/mt.2015.173. Epub 2016 Dec 5. Review. PubMed PMID: 28142019.

23.

Halliday GM (2015) Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement. Brain 138(Pt 8):2116–2119. doi:10.1093/brain/awv151 CrossRefPubMed

24.

Hermonat PL, Muzyczka N (1984) Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 81(20):6466–6470CrossRefPubMedPubMedCentral

25.

Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M et al (2008) Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 16(10):1737–1744. doi:10.1038/mt.2008.170 Epub 2008 Aug 26CrossRefPubMed

26.

Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63(1):43–52CrossRefPubMed

27.

Jecmenica-Lukic M, Poewe W, Tolosa E (2012) Wenning GK (2012) Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 11:361–368CrossRefPubMed

28.

Jellinger KA (2014) Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord 29(14):1720–1741. doi:10.1002/mds.26052 CrossRefPubMed

29.

Jellinger KA (2015) Multiple system atrophy—a synucleinopathy with specific glioneuronal degeneration. Austin J Clin Neurol 2:1071

30.

Jin H, Ishikawa K, Tsunemi T, Ishiguro T, Amino T, Mizusawa H (2008) Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J Med Dent Sci 55(1):145–153PubMed

31.

Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W et al (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3(6):583–588CrossRefPubMedPubMedCentral

32.

Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604–2612CrossRefPubMed

33.

Kuzdas D, Stemberger S, Gaburro S, Stefanova N, Singewald N, Wenning GK Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp Neurol 247:531–536

34.

Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692–1702CrossRefPubMedPubMedCentral

35.

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719. doi:10.1016/S1474-4422(15)00058-7 CrossRefPubMedPubMedCentral

36.

Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ (2007) rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 207(2):289–301 Epub 2007 Jul 10CrossRefPubMed

37.

Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 112(12):1613–1624. doi:10.1007/s00702-005-0378-1 CrossRefPubMed

38.

O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL et al (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131(Pt 5):1362–1372. doi:10.1093/brain/awn065 CrossRefPubMed

39.

Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S (2001) Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 102(2):188–190PubMed

40.

Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671CrossRefPubMed

41.

Papapetropoulos S, Tuchman A, Laufer D, Papatsoris AG, Papapetropoulos N, Mash DC (2007) Causes of death in multiple system atrophy. J Neurol Neurosurg Psychiatry 78(3):327–329CrossRefPubMedPubMedCentral

42.

Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and shy-Drager syndrome). J Neurol Sci 94(1–3):79–100CrossRefPubMed

43.

Papp MI, Lantos PL (1994) The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 117(Pt 2):235–243CrossRefPubMed

44.

Powell SK, Khan N, Parker CL, Samulski RJ, Matsushima G, Gray SJ, McCown TJ (2016) Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism. Gene Ther 23(11):807–814. doi:10.1038/gt.2016.62 Epub 2016 Sep 15CrossRefPubMed

45.

Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB et al (2015) Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 112(38):E5308–E5317. doi:10.1073/pnas.1514475112 CrossRefPubMedPubMedCentral

46.

Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ (2007) Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15(8):1504–1511CrossRefPubMed

47.

Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E (2014 Mar) (2014) alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62(3):387–398. doi:10.1002/glia.22611 CrossRefPubMed

48.

Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) Alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62(1):9–14CrossRefPubMed

49.

Salvesen L, Ullerup BH, Sunay FB, Brudek T, Løkkegaard A, Agander TK et al (2015) Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy - a stereological study. Neurobiol Dis 74:104–113. doi:10.1016/j.nbd.2014.11.008 Epub 2014 Nov 21CrossRefPubMed

50.

Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y (2008) Survival in multiple system atrophy. Mov Disord 23(2):294–296. doi:10.1002/mds.21839 CrossRefPubMed

51.

Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G et al (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25:10689–10699CrossRefPubMed

52.

Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ et al (2005) Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166:869–876CrossRefPubMedPubMedCentral

53.

Stemberger S, Poewe W, Wenning GK, Stefanova N (2010) Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol 224:459–464CrossRefPubMedPubMedCentral

54.

Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S et al (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44:415–422CrossRefPubMed

55.

Ubhi K, Low P, Masliah E (2011) Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 34:581–590CrossRefPubMedPubMedCentral

56.

Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C et al (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of Oligodendroglial-derived Neurotrophic factors. J Neurosci 30(18):6236–6246. doi:10.1523/JNEUROSCI.0567-10.2010 CrossRefPubMedPubMedCentral

57.

Ulusoy A, Decressac M, Kirik D, Björklund A (2010) Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Prog Brain Res 184:89–111. doi:10.1016/S0079-6123(10)84005-1 CrossRefPubMed

58.

Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M et al (1998b) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96:445–452CrossRefPubMed

59.

Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998a) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180–182CrossRefPubMed

60.

Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E et al (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125(Pt 5):1070–1083CrossRefPubMed

61.

Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM et al (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 110(48):19555–19560. doi:10.1073/pnas.1318268110 CrossRefPubMedPubMedCentral

62.

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12(3):264–274. doi:10.1016/S1474-4422(12)70327-7 Epub 2013 Feb 5CrossRefPubMedPubMedCentral

63.

Wenning GK, Shlomo YB, Mangalhaes M, Danie S, Quinn N (2008a) Clinical features and natural history of multiple system atrophy. Brain 117(4):835–845CrossRef

64.

Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG (2008b) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239–246CrossRefPubMed

65.

Wenning G, Tison F, Ben Shlomo Y, Daniel S, Quinn N (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12(2):133–147CrossRefPubMed

66.

West MJ, Gundersen HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296:1–22CrossRefPubMed

67.

Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K et al (2005) Mouse model of multiple system atrophy α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847–859CrossRefPubMed

68.

Yoshida M (2007) Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27(5):484–493CrossRefPubMed

Title: Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates
Authors: Ronald J. Mandel
David J. Marmion
Deniz Kirik
Yaping Chu
Clifford Heindel
Thomas McCown
Steven J. Gray
Jeffrey H. Kordower
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2017
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-017-0451-7

At a glance: The STEP trials

Springer Medicine

Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas

Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma

Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis

Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis